Clinical Trial Update: Safety and Effects of a Single Intravitreal Injection of vMCO-010 Optogenetic Therapy in Subjects With Stargardt Disease [Phase 2]

View source ↗

Summary

Phase 2 trial update on safety and effects of a single intravitreal injection of vMCO-010 optogenetic therapy in Stargardt disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Stargardt Disease

Drugs mentioned

• vMCO-010

Snippet

Sponsor: Nanoscope Therapeutics Inc. | Conditions: Stargardt Disease | Phase 2 | Status: COMPLETED